Condition 1: Myopia. Condition 2: Hypermetropia. Condition 3: Astigmatism. Condition 4: Other specified postprocedural states. Condition 5: Unspecified disorder of refraction. Myopia Hypermetropia Astigmatism Other specified postprocedural states Unspecified disorder of refraction
Conditions
Interventions
Intervention 1: Intervention group(Exosome):Treatment: Topical exosome eye drops derived from human umbilical cord mesenchymal stem cells (Arotamin company).Dose/Frequency: One drop every 4 hours.Note
patients also receive standard PRK postoperative medications and bandage contact lens. Intervention 2: Control group: Treatment: Balanced Salt Solution (BSS) placebo eye drops in identical, masked via
Sponsors
Bagheiat-allah University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Age over 18 years Indication for PRK surgery Willingness to participate in the study (informed consent) No concurrent cataract No nasolacrimal duct obstruction No eyelid margin infections (blepharitis) No pterygium or other fibrovascular ocular surface diseases No retinal diseases or glaucoma No systemic diseases interfering with corneal epithelial healing, such as diabetes or malnutrition
Exclusion criteria
Exclusion criteria: Failure to return for follow-up appointments after surgery Postoperative corneal surface infections such as corneal ulcers Failure to use prescribed eye drops as directed
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Time to complete corneal epithelial healing. Timepoint: Postoperative days 1, 2, 5, and 7 (until complete closure). Method of measurement: Application of sterile fluorescein strip and cobalt blue illumination under slit-lamp.Measurement of defect size (length × width in mm) using slit-lamp graticule.Recording of “complete/not complete closure” and calculation of time (days) to full re-epithelialization. | — |
Secondary
| Measure | Time frame |
|---|---|
| Early ocular surface healing and symptoms(Corneal epithelial defect size,Conjunctival injection (redness),Pain score). Timepoint: Days 1, 2, 5, and 7. Method of measurement: Fluorescein staining under slit-lamp; measurement with calibrated graticule (mm² or length × width).Standard grading based on the American Academy of Ophthalmology reference chart.Visual Analog Scale (VAS 0–10) recorded in the checklist.;Corneal clarity and visual acuity. Timepoint: Months 1, 3, and 6. Method of measurement: Standard slit-lamp haze grading; documented in questionnaire.Snellen or LogMAR chart.;Dry eye assessment. Timepoint: Months 1, 3, and 6. Method of measurement: Fluorescein dye instillation, cobalt blue slit-lamp; time (seconds) until first dry spot appears.Sterile strip placed in lower fornix; length of wetting (mm) after standard duration.Clinical evaluation with slit-lamp; recorded in mm. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactAhmad Vahidi
Bagheiat-allah University of Medical Sciences
Outcome results
None listed